C₂N Diagnostics, a St. Louis, MO-based brain health diagnostics company, received up to USD15M in investment from Eisai.
The company intends to use the funds to expand the availability, accessibility and use of blood biomarker tests for the early diagnosis of Alzheimer’s disease in the U.S.
Led by CEO Dr. Joel Braunstein, C₂N is a diagnostics company that offer clinical laboratory services and advanced diagnostic solutions in the field of brain health. Its mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring, optimizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration, and providing tools to help healthcare researchers understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health.
The company’s assays have been used in over 150 Alzheimer’s disease and other research studies throughout the U.S. and the world. C₂N has ongoing collaborations with multi-national pharmaceutical and biotech companies, academic institutions, National Institute on Aging, Alzheimer’s association, and other non-profits and consortiums. Over 15,000 Precivity™-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review.
Commenting on the news, Dr. Joel Braunstein said: “We greatly appreciate the dedication and thoroughness Eisai brought to evaluating the value and quality of our advanced diagnostic solutions in the field of brain health. With this financing, we’re building on our history of attracting the highest-quality investors committed to changing the trajectory of Alzheimer’s disease through early detection and treatment and, ultimately, prevention. We’re proud to have Eisai’s leadership in the field as we’re transforming the management and clinical care standard for patients with Alzheimer’s disease. The availability of blood biomarkers that are closely correlated with gold standard measures, such as positron emission tomography (PET) scans, will improve accessibility for patients to obtain safe and effective drug treatments as more become available.”
FinSMEs
07/03/2024